JMP Securities raised the firm’s price target on Madrigal Pharmaceuticals to $397 from $351 and keeps an Outperform rating on the shares. The firm is “pleased” the FDA provided a “clean” label for Rezdiffra and it is a clear win for Madrigal as the first approved noncirrhotic non-alcoholic steatohepatitis drug, the analyst tells investors in a research note. The firm sees Madrigal becoming the source of M&A speculation as the NASH launch should be strong and Rezdiffra’s first-to-market advantage will be meaningful.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDGL:
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
- Madrigal Pharmaceuticals price target raised to $405 from $275 at H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $338 from $336 at Canaccord
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals initiated with a Buy at Citi
